US2677682A
(en)
|
1951-08-24 |
1954-05-04 |
American Cyanamid Co |
Sulfonamido pteridines
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
US8933236B2
(en)
|
2012-05-22 |
2015-01-13 |
Xenon Pharmaceuticals Inc. |
N-substituted benzamides and methods of use thereof
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
US7332612B2
(en)
|
2001-11-14 |
2008-02-19 |
Teva Pharmaceutical Industries Ltd. |
Amorphous and crystalline forms of losartan potassium and process for their preparation
|
ZA200604578B
(en)
|
2003-11-14 |
2008-05-28 |
Vertex Pharma |
Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters
|
ES2631362T3
(es)
|
2004-01-30 |
2017-08-30 |
Vertex Pharmaceuticals Incorporated |
Moduladores de transportadores de casete de unión a ATP
|
BRPI0511321B8
(pt)
|
2004-06-24 |
2021-05-25 |
Vertex Pharma |
moduladores de transportadores de cassete de ligação de atp, composição farmacêutica e seus usos
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
AU2006279810B2
(en)
|
2005-08-11 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2007053641A2
(en)
|
2005-11-01 |
2007-05-10 |
Mars, Incorporated |
A-type procyanidins and inflammation
|
EP1974212A1
(en)
|
2005-12-27 |
2008-10-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
NZ569327A
(en)
|
2005-12-28 |
2011-09-30 |
Vertex Pharma |
1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
RS60205B1
(sr)
|
2005-12-28 |
2020-06-30 |
Vertex Pharma |
Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
|
HUE027630T2
(en)
|
2006-04-07 |
2016-10-28 |
Vertex Pharma |
Modulators of ATP-binding cassette transporters
|
US7553855B2
(en)
|
2006-05-12 |
2009-06-30 |
Vertex Pharmaceuticals Incorporated |
Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
CN101715450B
(zh)
|
2006-11-03 |
2013-03-13 |
沃泰克斯药物股份有限公司 |
作为cftr调控剂的氮杂吲哚衍生物
|
BRPI0811065A2
(pt)
|
2007-06-08 |
2014-12-02 |
Abbott Lab |
Indazóis 5-heteroaril substituídos como inibidores de quinase
|
NZ583848A
(en)
|
2007-09-14 |
2012-07-27 |
Vertex Pharma |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
PL2639222T3
(pl)
|
2007-12-07 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Sposób wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
|
CN103626744B
(zh)
|
2007-12-07 |
2016-05-11 |
沃泰克斯药物股份有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
|
EP2271622B1
(en)
|
2008-02-28 |
2017-10-04 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as CFTR Modulators
|
MX366161B
(es)
|
2008-08-13 |
2019-07-01 |
Vertex Pharmaceutical Incorporated |
Composicion farmaceutica y su administracion.
|
WO2010048526A2
(en)
|
2008-10-23 |
2010-04-29 |
Vertex Pharmaceuticals, Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
KR101559963B1
(ko)
|
2008-11-06 |
2015-10-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Atp-결합 카세트 수송자의 조절자
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
PL2408750T3
(pl)
|
2009-03-20 |
2016-02-29 |
Vertex Pharma |
Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
|
CA2938650C
(en)
|
2009-09-04 |
2018-01-09 |
Raptor Pharmaceuticals Inc. |
Use of aerosolized levofloxacin for treating cystic fibrosis
|
US20110098311A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorported |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
CA2792207A1
(en)
|
2010-03-19 |
2011-09-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
HUE052759T2
(hu)
|
2010-03-25 |
2021-05-28 |
Vertex Pharma |
(R)-1(2,2-difluorbenzo(D)(1,3)dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi-2- metilpropán-2-il)-1H-indol-5-il)-ciklo-propánkarboxamid amorf formájának szilárd diszperziója
|
EP4005559B1
(en)
|
2010-04-07 |
2025-02-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
|
HRP20160682T1
(hr)
|
2010-04-07 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
|
WO2011133951A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
MX353408B
(es)
|
2010-04-22 |
2018-01-11 |
Vertex Pharma |
Proceso para producir compuestos de cicloalquilcarboxamido-indol.
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
JP2013536231A
(ja)
|
2010-08-23 |
2013-09-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
(r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与
|
WO2012027731A2
(en)
|
2010-08-27 |
2012-03-01 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
WO2012093773A2
(ko)
|
2011-01-04 |
2012-07-12 |
에이큐 주식회사 |
광고 정보 제공 시스템
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
JP6063455B2
(ja)
|
2011-05-18 |
2017-01-18 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたイバカフトルの誘導体
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
BR112014010368A2
(pt)
|
2011-10-31 |
2017-04-25 |
Xenon Pharmaceuticals Inc |
biaril éter sulfonamidas e seu uso como agentes terapêuticos
|
US9254291B2
(en)
|
2011-11-08 |
2016-02-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
RS59262B1
(sr)
|
2012-01-25 |
2019-10-31 |
Vertex Pharma |
Formulacije 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
|
WO2013130669A1
(en)
|
2012-02-27 |
2013-09-06 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
AU2012377446A1
(en)
|
2012-04-20 |
2014-10-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
EP2858645A1
(en)
|
2012-06-08 |
2015-04-15 |
Vertex Pharmaceuticals Incorporated |
Pharmaceuticl compositions for the treatment of cftr -mediated disorders
|
WO2014014841A1
(en)
|
2012-07-16 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
SG10201913581UA
(en)
|
2012-11-02 |
2020-02-27 |
Vertex Pharma |
Pharmaceutical compositions for the treatment of cftr mediated diseases
|
WO2014078842A1
(en)
|
2012-11-19 |
2014-05-22 |
Concert Pharmaceuticals, Inc. |
Deuterated cftr potentiators
|
WO2015051043A1
(en)
|
2013-10-01 |
2015-04-09 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
CN105848657B
(zh)
|
2013-11-12 |
2020-05-22 |
沃泰克斯药物股份有限公司 |
制备用于治疗cftr介导的疾病的药物组合物的方法
|
PL3925607T3
(pl)
|
2014-04-15 |
2023-10-30 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
|
US9782408B2
(en)
|
2014-10-06 |
2017-10-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP3204358B1
(en)
|
2014-10-07 |
2018-09-19 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
RS62259B1
(sr)
|
2014-11-18 |
2021-09-30 |
Vertex Pharma |
Proces izvođenja ispitivanja visoke propusnosti tečne hromatografije visokih performansi
|
WO2016121399A1
(ja)
|
2015-01-29 |
2016-08-04 |
京セラ株式会社 |
測定装置およびセンサシステム
|
AU2016243171B2
(en)
|
2015-03-31 |
2020-10-08 |
Concert Pharmaceuticals, Inc. |
Deuterated VX-661
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
US20180353500A1
(en)
|
2015-09-21 |
2018-12-13 |
Vertex Pharmaceuticals (Europe) Limited |
Administration of deuterated cftr potentiators
|
MA42954A
(fr)
|
2015-09-25 |
2018-08-01 |
Vertex Pharmaceuticals Europe Ltd |
Potentialisateurs cftr deutérés
|
CN109071426A
(zh)
|
2016-03-30 |
2018-12-21 |
基因泰克公司 |
取代的苯甲酰胺及其使用方法
|
EP3436446B1
(en)
|
2016-03-31 |
2023-06-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CA3019663A1
(en)
|
2016-04-07 |
2017-10-12 |
Proteostasis Therapeutics, Inc. |
Ivacaftor analogues containing silicone atoms
|
EP3448842A1
(en)
|
2016-04-26 |
2019-03-06 |
AbbVie S.À.R.L. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
WO2017223188A1
(en)
|
2016-06-21 |
2017-12-28 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
US20180012171A1
(en)
|
2016-07-05 |
2018-01-11 |
Elie Massabki |
On-demand resource allocation
|
TW201811766A
(zh)
|
2016-08-29 |
2018-04-01 |
瑞士商諾華公司 |
N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
|
AU2017336156B2
(en)
|
2016-09-30 |
2021-10-21 |
Vertex Pharmaceuticals Incorporated |
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
AU2017348186A1
(en)
|
2016-10-26 |
2019-05-16 |
Proteostasis Therapeutics, Inc |
Pyridazine derivatives, compositions and methods for modulating CFTR
|
US20190256474A1
(en)
|
2016-10-26 |
2019-08-22 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
AU2017348183A1
(en)
|
2016-10-26 |
2019-05-16 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating CFTR
|
CA3041819A1
(en)
|
2016-10-27 |
2018-05-03 |
Vertex Pharmaceuticals (Europe) Limited |
Methods of treatment with deuterated cftr potentiators
|
NZ754085A
(en)
|
2016-11-18 |
2025-05-02 |
Cystic Fibrosis Found |
Pyrrolopyrimidines as cftr potentiators
|
MX2021013639A
(es)
|
2016-12-09 |
2022-09-30 |
Vertex Pharma |
Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
|
CA3046968A1
(en)
|
2016-12-16 |
2018-06-21 |
Joseph Walter Strohbach |
Bicyclic heteroaryl derivatives as cftr potentiators
|
US20200123137A1
(en)
|
2016-12-20 |
2020-04-23 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
CN110177788B
(zh)
|
2017-01-07 |
2023-03-24 |
重庆复创医药研究有限公司 |
作为bcl-2选择性凋亡诱导剂的化合物
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|
KR20190135029A
(ko)
|
2017-03-30 |
2019-12-05 |
에프. 호프만-라 로슈 아게 |
Hpk1의 억제제인 이소퀴놀린
|
MA49061A
(fr)
|
2017-04-28 |
2021-04-21 |
Proteostasis Therapeutics Inc |
Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
|
WO2018227049A1
(en)
|
2017-06-08 |
2018-12-13 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
US20210069174A1
(en)
|
2017-07-01 |
2021-03-11 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
MA49566A
(fr)
|
2017-07-11 |
2020-05-20 |
Vertex Pharma |
Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
|
CA3069225A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
AU2018304168B2
(en)
|
2017-07-17 |
2023-05-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
TWI799435B
(zh)
|
2017-08-02 |
2023-04-21 |
美商維泰克斯製藥公司 |
製備化合物之製程
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
EP3691638B1
(en)
|
2017-10-06 |
2024-12-11 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods for increasing cftr activity
|
EP3697774A1
(en)
|
2017-10-19 |
2020-08-26 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of cftr modulators
|
EP4484402A3
(en)
|
2017-12-01 |
2025-07-02 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
WO2019113476A2
(en)
|
2017-12-08 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
MX2020008268A
(es)
|
2018-02-15 |
2020-09-21 |
Vertex Pharma |
Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
|
WO2019191620A1
(en)
|
2018-03-30 |
2019-10-03 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of modulators of cftr
|
US20210139514A1
(en)
|
2018-04-05 |
2021-05-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US11414439B2
(en)
*
|
2018-04-13 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
EP4218754A3
(en)
|
2018-11-14 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
WO2020128925A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Macrocyclic compounds and their use in the treatment of disease
|
EP3921313A1
(en)
|
2019-02-06 |
2021-12-15 |
Novartis AG |
N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
|
WO2020191227A1
(en)
|
2019-03-20 |
2020-09-24 |
Cornell University |
Methods for controlling prostaglandin-mediated biological processes
|
AR118555A1
(es)
|
2019-04-03 |
2021-10-20 |
Vertex Pharma |
Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
TWI867024B
(zh)
|
2019-08-14 |
2024-12-21 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
US20220313698A1
(en)
|
2019-08-14 |
2022-10-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
MX2022001828A
(es)
|
2019-08-14 |
2022-06-08 |
Vertex Pharma |
Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
|
AU2020382827A1
(en)
|
2019-11-12 |
2022-05-26 |
Genzyme Corporation |
6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
|
JP7721517B2
(ja)
|
2019-11-12 |
2025-08-12 |
ジェンザイム・コーポレーション |
Cftr活性の欠損が介在する状態を治療するための5員ヘテロアリールアミノスルホンアミド
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
KR20230051216A
(ko)
|
2020-08-13 |
2023-04-17 |
버텍스 파마슈티칼스 인코포레이티드 |
Cftr 조절제의 결정질 형태
|
EP4225761A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20240150377A1
(en)
|
2020-10-07 |
2024-05-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225446A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20230382925A1
(en)
|
2020-10-07 |
2023-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CN116670143A
(zh)
|
2020-10-07 |
2023-08-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调控因子的调节剂
|
EP4225763A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
KR20230118123A
(ko)
|
2020-12-10 |
2023-08-10 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 치료 방법
|